Please login to the form below

Not currently logged in
Email:
Password:

BMS, ImClone and Merck KGaA to develop and sell Erbitux in Japan

ImClone Systems and Bristol-Myers Squibb (BMS) have established an agreement with Merck KGaA for the development and commercialisation of Erbitux (cetuximab) in Japan.

ImClone Systems and Bristol-Myers Squibb (BMS) have established an agreement with Merck KGaA for the development and commercialisation of Erbitux (cetuximab) in Japan.

Per the agreement, ImClone, BMS and Merck KGaA will collaborate on a joint effort to develop and, following regulatory approval, market Erbitux in Japan for the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC), as well as for the treatment of any other cancers the parties agree to pursue.

BMS and Merck KGaA will use their respective sales forces in Japan, and the three companies will share profits/losses. Merck Serono Japan will distribute the product and record the sales for the collaboration.

Merck KGaA will receive 50 per cent of the profit/loss from sales in Japan, while ImClone Systems and BMS will each receive 25 per cent. The sharing of profit/loss reflects the co- exclusive rights to Erbitux in Japan, previously granted by ImClone Systems to Merck KGaA and BMS. In addition to its percentage of profits, ImClone Systems will receive from Merck KGaA a royalty equal to 4.75 percent of total net sales in Japan.

ImClone Systems, BMS and Merck KGaA submitted an application in Japan earlier in 2007 for the use of Erbitux in treating patients with EGFR-expressing mCRC. The submission is a result of development collaboration among the three companies and is based on results from studies conducted in North America, the EU and Japan. Erbitux is the first monoclonal antibody that inhibits EGFR to be submitted for marketing authorisation in Japan.

John H Johnson, ImClone's CEO, said: "We are pleased to have established this agreement with our Erbitux partners BMS and Merck KGaA. Doing so puts the companies in a solid position to make Erbitux available to EGFR-expressing metastatic colorectal cancer patients in Japan upon a final decision from Japanese regulatory officials."

Lamberto Andreotti, executive vice-president and COO of worldwide pharmaceuticals at BMS, said: "This agreement further strengthens our partnership with ImClone Systems and Merck KGaA as we focus on maximizing the global potential of Erbitux. If approved in Japan, Erbitux would be an important new addition to the treatments available to Japanese patients with EGFR-expressing metastatic colorectal cancer."

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics